Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 04 April, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 531768 | NSE: POLYMED

Poly Medicure Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 2, 2025, 9:19 pm

Market Cap 22,202 Cr.
Current Price 2,191
High / Low 3,358/1,489
Stock P/E70.5
Book Value 256
Dividend Yield0.14 %
ROCE23.6 %
ROE19.1 %
Face Value 5.00
PEG Ratio4.01

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Poly Medicure Ltd

Competitors of Poly Medicure Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Constronics Infra Ltd 86.9 Cr. 69.3 158/40.031.5 22.90.00 %20.8 %118 % 10.0
Centenial Surgical Suture Ltd 42.0 Cr. 115 170/82.2 89.50.00 %8.07 %3.57 % 10.0
Adeshwar Meditex Ltd 23.1 Cr. 16.0 31.0/15.010.6 24.80.00 %9.62 %5.93 % 10.0
Poly Medicure Ltd 22,202 Cr. 2,191 3,358/1,48970.5 2560.14 %23.6 %19.1 % 5.00
Mohini Health & Hygiene Ltd 105 Cr. 57.8 86.9/46.010.1 57.20.87 %14.5 %11.1 % 10.0
Industry Average11,153.50 Cr489.8230.6890.080.20%15.32%31.54%9.00

All Competitor Stocks of Poly Medicure Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 230258249275285307321337340378385420424
Expenses 179202202210214224234253249281281305310
Operating Profit 51564665718387849097104115115
OPM % 22%22%19%24%25%27%27%25%27%26%27%27%27%
Other Income 885915914151715172724
Interest -1110522233333
Depreciation 14141414141516161616202122
Profit before tax 4649365967758381889298118113
Tax % 25%26%26%27%25%22%24%23%26%26%25%26%25%
Net Profit 35362744505963626568748785
EPS in Rs 3.603.772.814.545.216.136.546.486.787.127.718.638.41

Last Updated: February 28, 2025, 5:50 pm

Below is a detailed analysis of the quarterly data for Poly Medicure Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹424.00 Cr.. The value appears strong and on an upward trend. It has increased from 420.00 Cr. (Sep 2024) to ₹424.00 Cr., marking an increase of 4.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹310.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 305.00 Cr. (Sep 2024) to ₹310.00 Cr., marking an increase of 5.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹115.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 115.00 Cr..
  • For OPM %, as of Dec 2024, the value is 27.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 27.00%.
  • For Other Income, as of Dec 2024, the value is ₹24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Sep 2024) to ₹24.00 Cr., marking a decrease of 3.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹3.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 3.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Sep 2024) to ₹22.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 118.00 Cr. (Sep 2024) to ₹113.00 Cr., marking a decrease of 5.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Sep 2024) to 25.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Dec 2024, the value is ₹85.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Sep 2024) to ₹85.00 Cr., marking a decrease of 2.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 8.41. The value appears to be declining and may need further review. It has decreased from 8.63 (Sep 2024) to 8.41, marking a decrease of 0.22.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:12 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 2593223904114545196106877859221,1151,3751,607
Expenses 2062463043233613974795205697078471,0131,177
Operating Profit 5376868893122131166216215267362430
OPM % 20%24%22%21%21%23%22%24%28%23%24%26%27%
Other Income 011288141620212240386083
Interest 7910108121420116111413
Depreciation 13141921242937414854576478
Profit before tax 336385657597100126180195237344422
Tax % 30%30%27%27%27%27%35%24%25%25%25%25%
Net Profit 2445624855716596136147179258315
EPS in Rs 2.755.117.075.476.258.007.4110.8614.1715.2818.6926.9131.87
Dividend Payout % 9%20%18%27%40%25%27%18%18%16%16%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)87.50%37.78%-22.58%14.58%29.09%-8.45%47.69%41.67%8.09%21.77%44.13%
Change in YoY Net Profit Growth (%)0.00%-49.72%-60.36%37.16%14.51%-37.54%56.14%-6.03%-33.58%13.68%22.37%

Poly Medicure Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:16%
5 Years:18%
3 Years:21%
TTM:23%
Compounded Profit Growth
10 Years:21%
5 Years:32%
3 Years:24%
TTM:27%
Stock Price CAGR
10 Years:24%
5 Years:57%
3 Years:36%
1 Year:44%
Return on Equity
10 Years:18%
5 Years:17%
3 Years:16%
Last Year:19%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 7:52 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 11222222444444444848484851
Reserves 1011241742072272943373919181,0401,1941,4222,541
Borrowings 49677982101133161207137127149174161
Other Liabilities 537389768594112126121163187214300
Total Liabilities 2142863643874575656547671,2241,3771,5771,8593,052
Fixed Assets 92123165182207265306363426488635867972
CWIP 8201014201819252143787662
Investments 43443178253543461321671,090
Other Assets 110140185187227264321354422499732748928
Total Assets 2142863643874575656547671,2241,3771,5771,8593,052

Below is a detailed analysis of the balance sheet data for Poly Medicure Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹51.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2024) to ₹51.00 Cr., marking an increase of 3.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹2,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,422.00 Cr. (Mar 2024) to ₹2,541.00 Cr., marking an increase of 1,119.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹161.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 174.00 Cr. (Mar 2024) to ₹161.00 Cr., marking a decrease of 13.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹300.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 214.00 Cr. (Mar 2024) to ₹300.00 Cr., marking an increase of 86.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹3,052.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,859.00 Cr. (Mar 2024) to ₹3,052.00 Cr., marking an increase of 1,193.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹972.00 Cr.. The value appears strong and on an upward trend. It has increased from 867.00 Cr. (Mar 2024) to ₹972.00 Cr., marking an increase of 105.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2024) to ₹62.00 Cr., marking a decrease of 14.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹1,090.00 Cr.. The value appears strong and on an upward trend. It has increased from 167.00 Cr. (Mar 2024) to ₹1,090.00 Cr., marking an increase of 923.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹928.00 Cr.. The value appears strong and on an upward trend. It has increased from 748.00 Cr. (Mar 2024) to ₹928.00 Cr., marking an increase of 180.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹3,052.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,859.00 Cr. (Mar 2024) to ₹3,052.00 Cr., marking an increase of 1,193.00 Cr..

Notably, the Reserves (₹2,541.00 Cr.) exceed the Borrowings (161.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +396663635675106128119123191266
Cash from Investing Activity +-31-58-59-31-56-88-101-107-436-85-179-241
Cash from Financing Activity +-85-6-31-016-5-21317-35-13-20
Net Cash Flow013-21031103-15

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow4.009.007.006.00-8.00-11.00-30.00-41.0079.0088.00118.00188.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days615259747779776872827772
Inventory Days149142148114194161186241217218237167
Days Payable99101101761319612314211111510572
Cash Conversion Cycle11194106111140144139166179185209166
Working Capital Days5631456581948373107116112136
ROCE %27%33%30%26%24%26%22%25%22%17%18%23%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters44.66%53.34%53.33%53.33%53.32%53.32%53.17%53.17%53.14%66.02%62.56%62.44%
FIIs15.07%15.59%16.27%16.33%16.21%15.61%14.49%14.10%12.37%9.91%11.88%12.33%
DIIs3.33%3.25%3.39%3.38%3.67%4.25%5.15%5.46%7.21%9.34%12.33%11.66%
Public36.94%27.82%27.02%26.97%26.79%26.82%27.20%27.28%27.25%14.72%13.23%13.57%
No. of Shareholders33,83133,29634,23932,01535,39336,14134,64936,05336,71236,85238,35260,686

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Flexi Cap Fund2,144,7731.24312.422,144,7732025-04-030%
Quant Small Cap Fund1,043,7520.97152.042,144,7732025-04-03-51.34%
UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan180,6090.526.312,144,7732025-04-03-91.58%
UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan180,6090.526.312,144,7732025-04-03-91.58%
WhiteOak Capital Flexi Cap Fund140,6380.6920.492,144,7732025-04-03-93.44%
Bank of India Small Cap Fund96,5001.5414.062,144,7732025-04-03-95.5%
UTI Healthcare Fund62,3280.999.082,144,7732025-04-03-97.09%
WhiteOak Capital Mid Cap Fund51,9060.497.562,144,7732025-04-03-97.58%
Bank of India ELSS Tax Saver49,7680.667.252,144,7732025-04-03-97.68%
Bank of India ELSS Tax Saver - Eco Plan49,7680.667.252,144,7732025-04-03-97.68%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 26.9218.6915.2815.2510.86
Diluted EPS (Rs.) 26.9018.6715.2715.2410.86
Cash EPS (Rs.) 33.3124.4420.6518.7815.21
Book Value[Excl.RevalReserv]/Share (Rs.) 153.18129.41113.40100.7149.27
Book Value[Incl.RevalReserv]/Share (Rs.) 153.18129.41113.40100.7149.27
Revenue From Operations / Share (Rs.) 143.35116.2496.2582.0377.88
PBDIT / Share (Rs.) 43.4531.4326.1724.2820.67
PBIT / Share (Rs.) 36.7925.4720.5519.3216.08
PBT / Share (Rs.) 35.6124.5520.1018.4314.00
Net Profit / Share (Rs.) 26.6518.4815.0213.8310.62
NP After MI And SOA / Share (Rs.) 26.9118.6915.2814.1710.86
PBDIT Margin (%) 30.3027.0427.1929.5926.54
PBIT Margin (%) 25.6621.9121.3423.5520.64
PBT Margin (%) 24.8321.1220.8822.4717.98
Net Profit Margin (%) 18.5815.9015.6016.8513.63
NP After MI And SOA Margin (%) 18.7716.0715.8717.2713.95
Return on Networth / Equity (%) 17.5614.4313.4714.0722.04
Return on Capital Employeed (%) 23.4219.0317.1317.6024.88
Return On Assets (%) 13.8911.3610.6411.1012.49
Long Term Debt / Equity (X) 0.000.010.030.060.25
Total Debt / Equity (X) 0.110.110.110.100.38
Asset Turnover Ratio (%) 0.800.730.680.760.92
Current Ratio (X) 2.402.753.464.121.61
Quick Ratio (X) 1.772.042.713.381.04
Inventory Turnover Ratio (X) 2.162.252.392.222.24
Dividend Payout Ratio (NP) (%) 11.1413.3716.360.0018.40
Dividend Payout Ratio (CP) (%) 8.9310.1411.950.0012.93
Earning Retention Ratio (%) 88.8686.6383.640.0081.60
Cash Earning Retention Ratio (%) 91.0789.8688.050.0087.07
Interest Coverage Ratio (X) 36.9034.1258.9927.359.96
Interest Coverage Ratio (Post Tax) (X) 23.6321.0734.8616.576.12
Enterprise Value (Cr.) 15271.329107.859208.877911.732221.33
EV / Net Operating Revenue (X) 11.108.179.9810.063.23
EV / EBITDA (X) 36.6230.2036.6933.9912.18
MarketCap / Net Operating Revenue (X) 11.088.209.869.973.03
Retention Ratios (%) 88.8586.6283.630.0081.59
Price / BV (X) 10.377.368.378.124.78
Price / Net Operating Revenue (X) 11.088.209.869.973.03
EarningsYield 0.010.010.010.010.04

After reviewing the key financial ratios for Poly Medicure Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 26.92. This value is within the healthy range. It has increased from 18.69 (Mar 23) to 26.92, marking an increase of 8.23.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 26.90. This value is within the healthy range. It has increased from 18.67 (Mar 23) to 26.90, marking an increase of 8.23.
  • For Cash EPS (Rs.), as of Mar 24, the value is 33.31. This value is within the healthy range. It has increased from 24.44 (Mar 23) to 33.31, marking an increase of 8.87.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 153.18. It has increased from 129.41 (Mar 23) to 153.18, marking an increase of 23.77.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 153.18. It has increased from 129.41 (Mar 23) to 153.18, marking an increase of 23.77.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.35. It has increased from 116.24 (Mar 23) to 143.35, marking an increase of 27.11.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 43.45. This value is within the healthy range. It has increased from 31.43 (Mar 23) to 43.45, marking an increase of 12.02.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 36.79. This value is within the healthy range. It has increased from 25.47 (Mar 23) to 36.79, marking an increase of 11.32.
  • For PBT / Share (Rs.), as of Mar 24, the value is 35.61. This value is within the healthy range. It has increased from 24.55 (Mar 23) to 35.61, marking an increase of 11.06.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 26.65. This value is within the healthy range. It has increased from 18.48 (Mar 23) to 26.65, marking an increase of 8.17.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 26.91. This value is within the healthy range. It has increased from 18.69 (Mar 23) to 26.91, marking an increase of 8.22.
  • For PBDIT Margin (%), as of Mar 24, the value is 30.30. This value is within the healthy range. It has increased from 27.04 (Mar 23) to 30.30, marking an increase of 3.26.
  • For PBIT Margin (%), as of Mar 24, the value is 25.66. This value exceeds the healthy maximum of 20. It has increased from 21.91 (Mar 23) to 25.66, marking an increase of 3.75.
  • For PBT Margin (%), as of Mar 24, the value is 24.83. This value is within the healthy range. It has increased from 21.12 (Mar 23) to 24.83, marking an increase of 3.71.
  • For Net Profit Margin (%), as of Mar 24, the value is 18.58. This value exceeds the healthy maximum of 10. It has increased from 15.90 (Mar 23) to 18.58, marking an increase of 2.68.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 18.77. This value is within the healthy range. It has increased from 16.07 (Mar 23) to 18.77, marking an increase of 2.70.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 17.56. This value is within the healthy range. It has increased from 14.43 (Mar 23) to 17.56, marking an increase of 3.13.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 23.42. This value is within the healthy range. It has increased from 19.03 (Mar 23) to 23.42, marking an increase of 4.39.
  • For Return On Assets (%), as of Mar 24, the value is 13.89. This value is within the healthy range. It has increased from 11.36 (Mar 23) to 13.89, marking an increase of 2.53.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 23) to 0.00, marking a decrease of 0.01.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.11. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.11.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.80. It has increased from 0.73 (Mar 23) to 0.80, marking an increase of 0.07.
  • For Current Ratio (X), as of Mar 24, the value is 2.40. This value is within the healthy range. It has decreased from 2.75 (Mar 23) to 2.40, marking a decrease of 0.35.
  • For Quick Ratio (X), as of Mar 24, the value is 1.77. This value is within the healthy range. It has decreased from 2.04 (Mar 23) to 1.77, marking a decrease of 0.27.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.16. This value is below the healthy minimum of 4. It has decreased from 2.25 (Mar 23) to 2.16, marking a decrease of 0.09.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 11.14. This value is below the healthy minimum of 20. It has decreased from 13.37 (Mar 23) to 11.14, marking a decrease of 2.23.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 8.93. This value is below the healthy minimum of 20. It has decreased from 10.14 (Mar 23) to 8.93, marking a decrease of 1.21.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 88.86. This value exceeds the healthy maximum of 70. It has increased from 86.63 (Mar 23) to 88.86, marking an increase of 2.23.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 91.07. This value exceeds the healthy maximum of 70. It has increased from 89.86 (Mar 23) to 91.07, marking an increase of 1.21.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 36.90. This value is within the healthy range. It has increased from 34.12 (Mar 23) to 36.90, marking an increase of 2.78.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 23.63. This value is within the healthy range. It has increased from 21.07 (Mar 23) to 23.63, marking an increase of 2.56.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 15,271.32. It has increased from 9,107.85 (Mar 23) to 15,271.32, marking an increase of 6,163.47.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 11.10. This value exceeds the healthy maximum of 3. It has increased from 8.17 (Mar 23) to 11.10, marking an increase of 2.93.
  • For EV / EBITDA (X), as of Mar 24, the value is 36.62. This value exceeds the healthy maximum of 15. It has increased from 30.20 (Mar 23) to 36.62, marking an increase of 6.42.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 11.08. This value exceeds the healthy maximum of 3. It has increased from 8.20 (Mar 23) to 11.08, marking an increase of 2.88.
  • For Retention Ratios (%), as of Mar 24, the value is 88.85. This value exceeds the healthy maximum of 70. It has increased from 86.62 (Mar 23) to 88.85, marking an increase of 2.23.
  • For Price / BV (X), as of Mar 24, the value is 10.37. This value exceeds the healthy maximum of 3. It has increased from 7.36 (Mar 23) to 10.37, marking an increase of 3.01.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 11.08. This value exceeds the healthy maximum of 3. It has increased from 8.20 (Mar 23) to 11.08, marking an increase of 2.88.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Poly Medicure Ltd as of April 4, 2025 is: 2,761.60

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 4, 2025, Poly Medicure Ltd is Undervalued by 26.04% compared to the current share price 2,191.00

Intrinsic Value of Poly Medicure Ltd as of April 4, 2025 is: 3,247.61

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 4, 2025, Poly Medicure Ltd is Undervalued by 48.23% compared to the current share price 2,191.00

Last 5 Year EPS CAGR: 17.60%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 24.42%, which is a positive sign.
  2. The company has higher reserves (690.00 cr) compared to borrowings (125.15 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (412.46 cr) and profit (155.54 cr) over the years.
  1. The stock has a high average Working Capital Days of 83.25, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 145.83, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Poly Medicure Ltd:
    1. Net Profit Margin: 18.58%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 23.42% (Industry Average ROCE: 15.32%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 17.56% (Industry Average ROE: 31.54%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 23.63
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.77
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 70.5 (Industry average Stock P/E: 30.68)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.11
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Poly Medicure Ltd. is a Public Limited Listed company incorporated on 30/03/1995 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L40300DL1995PLC066923 and registration number is 066923. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company's Total Operating Revenue is Rs. 1307.25 Cr. and Equity Capital is Rs. 47.99 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Medical Equipment & AccessoriesNo. 232-B, 3rd Floor, New Delhi Delhi 110020investorcare@polymedicure.com
http://www.polymedicure.com
Management
NamePosition Held
Mr. Devendra Raj MehtaChairman
Mr. Himanshu BaidManaging Director
Mr. Rishi BaidJoint Managing Director
Mr. Jugal Kishore BaidNon Executive Director
Mrs. Mukulika BaidNon Executive Director
Mr. Alessandro BalboniNon Executive Director
Dr. Shailendra Raj MehtaInd. Non-Executive Director
Dr. Ambrish MithalInd. Non-Executive Director
Dr. Sandeep BhargavaInd. Non-Executive Director
Mr. Vimal BhandariInd. Non-Executive Director
Mr. Amit KhoslaInd. Non-Executive Director
Ms. Sonal MattooInd. Non-Executive Director

FAQ

What is the intrinsic value of Poly Medicure Ltd?

Poly Medicure Ltd's intrinsic value (as of 03 April 2025) is ₹2761.60 — 26.04% higher the current market price of ₹2,191.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 22,202 Cr. market cap, FY2025-2026 high/low of ₹3,358/1,489, reserves of 2,541 Cr, and liabilities of 3,052 Cr.

What is the Market Cap of Poly Medicure Ltd?

The Market Cap of Poly Medicure Ltd is 22,202 Cr..

What is the current Stock Price of Poly Medicure Ltd as on 03 April 2025?

The current stock price of Poly Medicure Ltd as on 03 April 2025 is 2,191.

What is the High / Low of Poly Medicure Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Poly Medicure Ltd stocks is ₹3,358/1,489.

What is the Stock P/E of Poly Medicure Ltd?

The Stock P/E of Poly Medicure Ltd is 70.5.

What is the Book Value of Poly Medicure Ltd?

The Book Value of Poly Medicure Ltd is 256.

What is the Dividend Yield of Poly Medicure Ltd?

The Dividend Yield of Poly Medicure Ltd is 0.14 %.

What is the ROCE of Poly Medicure Ltd?

The ROCE of Poly Medicure Ltd is 23.6 %.

What is the ROE of Poly Medicure Ltd?

The ROE of Poly Medicure Ltd is 19.1 %.

What is the Face Value of Poly Medicure Ltd?

The Face Value of Poly Medicure Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Poly Medicure Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE